Four-year outcome of a PI and NRTI-sparing salvage regimen: Maraviroc, raltegravir, etravirine

Silvi Nozza, Laur Galli, Alb Bigoloni, Nicol Gianotti, Vincenz Spagnuolo, Alessi Carbone, Stefani Chiappetta, Marc Ripa, Giusepp Tambussi, Adrian Lazzarin, Antonell Castagna

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Aim of this study was to report the 204-week efficacy and safety results of a novel PI- and NRTI-sparing regimen for salvage therapy including maraviroc, raltegravir, etravirine in 28 failing HIV-infected patients with R5-tropic virus. The trend of laboratory parameters was tested by ANOVA for repeated measures and Greenhouse-Geisser probabilities were reported. Results were described as median (Q1-Q3) values. Twenty-six (93%) out of 28 patients completed 204 weeks of treatment. Virological success (HIV-RNA

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalNew Microbiologica
Volume37
Issue number2
Publication statusPublished - 2014

Fingerprint

etravirine
HIV
Salvage Therapy
Analysis of Variance
RNA
Viruses
Safety
maraviroc
Raltegravir Potassium
Therapeutics

Keywords

  • Etravirine
  • Maraviroc
  • Raltegravir

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Four-year outcome of a PI and NRTI-sparing salvage regimen : Maraviroc, raltegravir, etravirine. / Nozza, Silvi; Galli, Laur; Bigoloni, Alb; Gianotti, Nicol; Spagnuolo, Vincenz; Carbone, Alessi; Chiappetta, Stefani; Ripa, Marc; Tambussi, Giusepp; Lazzarin, Adrian; Castagna, Antonell.

In: New Microbiologica, Vol. 37, No. 2, 2014, p. 145-151.

Research output: Contribution to journalArticle

Nozza, S, Galli, L, Bigoloni, A, Gianotti, N, Spagnuolo, V, Carbone, A, Chiappetta, S, Ripa, M, Tambussi, G, Lazzarin, A & Castagna, A 2014, 'Four-year outcome of a PI and NRTI-sparing salvage regimen: Maraviroc, raltegravir, etravirine', New Microbiologica, vol. 37, no. 2, pp. 145-151.
Nozza, Silvi ; Galli, Laur ; Bigoloni, Alb ; Gianotti, Nicol ; Spagnuolo, Vincenz ; Carbone, Alessi ; Chiappetta, Stefani ; Ripa, Marc ; Tambussi, Giusepp ; Lazzarin, Adrian ; Castagna, Antonell. / Four-year outcome of a PI and NRTI-sparing salvage regimen : Maraviroc, raltegravir, etravirine. In: New Microbiologica. 2014 ; Vol. 37, No. 2. pp. 145-151.
@article{db78849fd35f40fdbbecab0e15e4fe18,
title = "Four-year outcome of a PI and NRTI-sparing salvage regimen: Maraviroc, raltegravir, etravirine",
abstract = "Aim of this study was to report the 204-week efficacy and safety results of a novel PI- and NRTI-sparing regimen for salvage therapy including maraviroc, raltegravir, etravirine in 28 failing HIV-infected patients with R5-tropic virus. The trend of laboratory parameters was tested by ANOVA for repeated measures and Greenhouse-Geisser probabilities were reported. Results were described as median (Q1-Q3) values. Twenty-six (93{\%}) out of 28 patients completed 204 weeks of treatment. Virological success (HIV-RNA",
keywords = "Etravirine, Maraviroc, Raltegravir",
author = "Silvi Nozza and Laur Galli and Alb Bigoloni and Nicol Gianotti and Vincenz Spagnuolo and Alessi Carbone and Stefani Chiappetta and Marc Ripa and Giusepp Tambussi and Adrian Lazzarin and Antonell Castagna",
year = "2014",
language = "English",
volume = "37",
pages = "145--151",
journal = "New Microbiologica",
issn = "1121-7138",
publisher = "Luigi Ponzio e figlio Editori",
number = "2",

}

TY - JOUR

T1 - Four-year outcome of a PI and NRTI-sparing salvage regimen

T2 - Maraviroc, raltegravir, etravirine

AU - Nozza, Silvi

AU - Galli, Laur

AU - Bigoloni, Alb

AU - Gianotti, Nicol

AU - Spagnuolo, Vincenz

AU - Carbone, Alessi

AU - Chiappetta, Stefani

AU - Ripa, Marc

AU - Tambussi, Giusepp

AU - Lazzarin, Adrian

AU - Castagna, Antonell

PY - 2014

Y1 - 2014

N2 - Aim of this study was to report the 204-week efficacy and safety results of a novel PI- and NRTI-sparing regimen for salvage therapy including maraviroc, raltegravir, etravirine in 28 failing HIV-infected patients with R5-tropic virus. The trend of laboratory parameters was tested by ANOVA for repeated measures and Greenhouse-Geisser probabilities were reported. Results were described as median (Q1-Q3) values. Twenty-six (93%) out of 28 patients completed 204 weeks of treatment. Virological success (HIV-RNA

AB - Aim of this study was to report the 204-week efficacy and safety results of a novel PI- and NRTI-sparing regimen for salvage therapy including maraviroc, raltegravir, etravirine in 28 failing HIV-infected patients with R5-tropic virus. The trend of laboratory parameters was tested by ANOVA for repeated measures and Greenhouse-Geisser probabilities were reported. Results were described as median (Q1-Q3) values. Twenty-six (93%) out of 28 patients completed 204 weeks of treatment. Virological success (HIV-RNA

KW - Etravirine

KW - Maraviroc

KW - Raltegravir

UR - http://www.scopus.com/inward/record.url?scp=84900420402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900420402&partnerID=8YFLogxK

M3 - Article

C2 - 24858641

AN - SCOPUS:84900420402

VL - 37

SP - 145

EP - 151

JO - New Microbiologica

JF - New Microbiologica

SN - 1121-7138

IS - 2

ER -